CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8(+) T cells in the tumor microenvironment.
Cancer-cell-derived fumarate suppresses the anti-tumor capacity of CD8(+) T cells in the tumor microenvironment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
微环境中的代谢改变显著调节肿瘤免疫敏感性,但其潜在机制仍不清楚。在此,我们报道,耗竭延胡索酸水合酶(FH)的肿瘤表现出功能性CD8+ T细胞活化、扩增和疗效的抑制,并具有增强的恶性增殖能力。机制上,肿瘤细胞中FH耗竭导致肿瘤间质液中延胡索酸积累,增加的延胡索酸可直接在C96和C102位点对浸润CD8+ T细胞中的ZAP70进行琥珀酰化并废除其活性,从而导致体外和体内CD8+ T细胞活化和抗肿瘤免疫应答受到抑制。此外,通过增加FH表达来耗竭延胡索酸可强烈增强抗CD19 CAR-T 细胞的抗肿瘤疗效。因此,这些发现证明了延胡索酸在控制TCR信号传导中的作用,并表明肿瘤微环境(TME)中延胡索酸积累是CD8+ T细胞抗肿瘤功能的代谢屏障。并且,耗竭延胡索酸可能成为肿瘤免疫治疗的重要策略。
Metabolic alterations in the microenvironment significantly modulate tumor immunosensitivity, but the underlying mechanisms remain obscure.
Here, we report that tumors depleted of fumarate hydratase (FH) exhibit inhibition of functional CD8 + T cell activation, expansion, and efficacy, with enhanced malignant proliferative capacity.
Mechanistically, FH depletion in tumor cells accumulates fumarate in the tumor interstitial fluid, and increased fumarate can directly succinate ZAP70 at C96 and C102 and abrogate its activity in infiltrating CD8 + T cells, resulting in suppressed CD8 + T cell activation and anti-tumor immune responses in vitro and in vivo.
Additionally, fumarate depletion by increasing FH expression strongly enhances the anti-tumor efficacy of anti-CD19 CAR T cells.
Thus, these findings demonstrate a role for fumarate in controlling TCR signaling and suggest that fumarate accumulation in the tumor microenvironment (TME) is a metabolic barrier to CD8 + T cell anti-tumor function. And potentially, fumarate depletion could be an important strategy for tumor immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。